7 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 7 of 7 clinical reviews.
A clinical guide to the legal status of compounded sildenafil (Viagra), including FDA regulations, 503A and 503B exemptions, patent history, and what the current rules mean for patients and prescribers.
A side-by-side comparison of FDA and EMA regulatory approaches to Viagra (sildenafil), covering approval timelines, label differences, OTC reclassification, post-market safety surveillance, and what these divergent paths mean for prescribers and patients.
A clinical deep-dive into the FDA FAERS database entries for Viagra (sildenafil), covering post-market safety signals, label updates, cardiovascular warnings, vision and hearing adverse events, and what the data means for prescribers and patients.
A comprehensive review of sildenafil (Viagra) regulatory status worldwide, including FDA approval history, EMA authorization, OTC reclassification in the UK, and ongoing post-market surveillance data.
A detailed timeline of every FDA label change to Viagra (sildenafil) from 2020 through 2026, covering safety warnings, drug interactions, contraindications, and post-market surveillance findings.
A detailed look at every major legal battle, patent dispute, and regulatory milestone in sildenafil's history, from FDA approval in 1998 through generic entry and beyond.
A clinical review of sildenafil's regulatory history, current FDA label, post-market safety data, and the next-generation PDE5 inhibitor pipeline for erectile dysfunction.